Form 4: Edwards Lifesciences Director Sells $218K in Stock

Edwards Lifesciences Director Leslie Stone Heisz reported the sale of 2,615 shares of common stock for approximately $218,000 on December 12, 2025.

Summary

• Leslie Stone Heisz, a Director at Edwards Lifesciences Corp (EW), sold 2,615 shares of common stock.
• The transaction occurred on December 12, 2025.
• The shares were sold at a price of $83.4109 per share, totaling approximately $218,000.
• Following this transaction, Leslie Stone Heisz beneficially owns 30,948 shares of Edwards Lifesciences common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating it was a pre-arranged sale.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while potentially viewed negatively, was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to new information. This mitigates the negative sentiment typically associated with insider sales.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, which suggests a pre-scheduled sale rather than a reaction to recent company news, potentially mitigating concerns about insider sentiment.

Negatives

• A director selling shares could be interpreted by some investors as a lack of confidence in the company's near-term prospects, although this is often a routine part of compensation or diversification.

Future Outlook

Not applicable.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe the director's sale and consider its implications for their investment decisions, though the 10b5-1 plan context often lessens concern.

Key Dates

Keywords

Edwards Lifesciences, EW, insider trading, stock sale, director, Leslie Stone Heisz, Form 4, 10b5-1 plan, beneficial ownership